Berry D D
Department of Pediatrics, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27103.
Clin Pediatr (Phila). 1991 Mar;30(3):167-72. doi: 10.1177/000992289103000306.
It has been more than 35 years since the lung was discovered to be lined with a layer of surface-active material that is important in lung stability and mechanics of respiration. The absence of this "anti-atelectasis" factor was proposed by Avery and Mead in 1959 to be the cause of hyaline membrane disease of premature infants. An indepth historical review of pulmonary surfactant by Tierney was recently published. In the years since 1959, there has been an exhaustive amount of research aimed at elucidating the structure and function of pulmonary surfactant, the ultimate goal being a safe and effective exogenous surfactant for the treatment of the Respiratory Distress Syndrome (RDS). The days of surfactant research are far from over, but the era of surfactant replacement therapy is now upon us. The practitioner needs to be knowledgeable about surfactant and aware of his or her role in surfactant therapy for premature infants. The following is intended to clarify some of the important issue of surfactant replacement.
自发现肺内衬有一层对肺稳定性和呼吸力学至关重要的表面活性物质以来，已有35年多的时间了。1959年，艾弗里（Avery）和米德（Mead）提出，缺乏这种“抗肺不张”因子是早产儿透明膜病的病因。蒂尔尼（Tierney）最近发表了一篇关于肺表面活性剂的深入历史回顾。自1959年以来的这些年里，人们进行了大量详尽的研究，旨在阐明肺表面活性剂的结构和功能，最终目标是找到一种安全有效的外源性表面活性剂来治疗呼吸窘迫综合征（RDS）。表面活性剂研究的日子远未结束，但表面活性剂替代疗法的时代现在已经来临。从业者需要了解表面活性剂，并意识到自己在早产儿表面活性剂治疗中的作用。以下内容旨在阐明表面活性剂替代的一些重要问题。
